Advances in COVID-19 mRNA vaccine development
E Fang, X Liu, M Li, Z Zhang, L Song, B Zhu… - Signal transduction and …, 2022 - nature.com
To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …
challenge in this century. Two years after its emergence, the rapid development and …
The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review
I Mohammed, A Nauman, P Paul… - Human vaccines & …, 2022 - Taylor & Francis
With the relatively rapid development of the COVID-19 pandemic, vaccine development has
become crucial for limiting disease transmission. The accelerated growth in the approved …
become crucial for limiting disease transmission. The accelerated growth in the approved …
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
M Sadarangani, A Marchant… - Nature Reviews …, 2021 - nature.com
Most COVID-19 vaccines are designed to elicit immune responses, ideally neutralizing
antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including …
antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including …
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
A Fendler, EGE de Vries… - Nature Reviews …, 2022 - nature.com
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …
associated mortality than the general population. Owing to this increased risk, patients with …
Final analysis of efficacy and safety of single-dose Ad26. COV2. S
J Sadoff, G Gray, A Vandebosch… - … England Journal of …, 2022 - Mass Medical Soc
Abstract Background The Ad26. COV2. S vaccine was highly effective against severe–
critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase …
critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase …
The humoral response and antibodies against SARS-CoV-2 infection
Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …
Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—a new coronavirus that
has led to a worldwide pandemic—has a furin cleavage site (PRRAR) in its spike protein …
has led to a worldwide pandemic—has a furin cleavage site (PRRAR) in its spike protein …
Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis
V Rotshild, B Hirsh-Raccah, I Miskin, M Muszkat… - Scientific reports, 2021 - nature.com
Abstract New Coronavirus Disease 2019 (COVID-19) vaccines are available to prevent the
ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. We …
ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. We …
Immunogenicity of Ad26. COV2. S vaccine against SARS-CoV-2 variants in humans
G Alter, J Yu, J Liu, A Chandrashekar, EN Borducchi… - Nature, 2021 - nature.com
Abstract The Ad26. COV2. S vaccine,–has demonstrated clinical efficacy against
symptomatic COVID-19, including against the B. 1.351 variant that is partially resistant to …
symptomatic COVID-19, including against the B. 1.351 variant that is partially resistant to …